382 related articles for article (PubMed ID: 23006513)
1. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
Tomicic MT; Kaina B
Biochim Biophys Acta; 2013 Jan; 1835(1):11-27. PubMed ID: 23006513
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
[TBL] [Abstract][Full Text] [Related]
3. Tipin functions in the protection against topoisomerase I inhibitor.
Hosono Y; Abe T; Higuchi M; Kajii K; Sakuraba S; Tada S; Enomoto T; Seki M
J Biol Chem; 2014 Apr; 289(16):11374-11384. PubMed ID: 24573676
[TBL] [Abstract][Full Text] [Related]
4. Loss of nonhomologous end joining confers camptothecin resistance in DT40 cells. Implications for the repair of topoisomerase I-mediated DNA damage.
Adachi N; So S; Koyama H
J Biol Chem; 2004 Sep; 279(36):37343-8. PubMed ID: 15218034
[TBL] [Abstract][Full Text] [Related]
5. DNA-PK triggers histone ubiquitination and signaling in response to DNA double-strand breaks produced during the repair of transcription-blocking topoisomerase I lesions.
Cristini A; Park JH; Capranico G; Legube G; Favre G; Sordet O
Nucleic Acids Res; 2016 Feb; 44(3):1161-78. PubMed ID: 26578593
[TBL] [Abstract][Full Text] [Related]
6. New Topoisomerase I mutations are associated with resistance to camptothecin.
Gongora C; Vezzio-Vie N; Tuduri S; Denis V; Causse A; Auzanneau C; Collod-Beroud G; Coquelle A; Pasero P; Pourquier P; Martineau P; Del Rio M
Mol Cancer; 2011 May; 10():64. PubMed ID: 21619602
[TBL] [Abstract][Full Text] [Related]
7. Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair.
Fujimori A; Gupta M; Hoki Y; Pommier Y
Mol Pharmacol; 1996 Dec; 50(6):1472-8. PubMed ID: 8967967
[TBL] [Abstract][Full Text] [Related]
8. Structural insight of DNA topoisomerases I from camptothecin-producing plants revealed by molecular dynamics simulations.
Sirikantaramas S; Meeprasert A; Rungrotmongkol T; Fuji H; Hoshino T; Sudo H; Yamazaki M; Saito K
Phytochemistry; 2015 May; 113():50-6. PubMed ID: 25733498
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase I poisoning results in PARP-mediated replication fork reversal.
Ray Chaudhuri A; Hashimoto Y; Herrador R; Neelsen KJ; Fachinetti D; Bermejo R; Cocito A; Costanzo V; Lopes M
Nat Struct Mol Biol; 2012 Mar; 19(4):417-23. PubMed ID: 22388737
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy.
Xu Y; Her C
Biomolecules; 2015 Jul; 5(3):1652-70. PubMed ID: 26287259
[TBL] [Abstract][Full Text] [Related]
11. Rad18 E3 ubiquitin ligase activity mediates Fanconi anemia pathway activation and cell survival following DNA Topoisomerase 1 inhibition.
Palle K; Vaziri C
Cell Cycle; 2011 May; 10(10):1625-38. PubMed ID: 21478670
[TBL] [Abstract][Full Text] [Related]
12. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.
Tanizawa A; Kohn KW; Kohlhagen G; Leteurtre F; Pommier Y
Biochemistry; 1995 May; 34(21):7200-6. PubMed ID: 7766631
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells.
Desai SD; Li TK; Rodriguez-Bauman A; Rubin EH; Liu LF
Cancer Res; 2001 Aug; 61(15):5926-32. PubMed ID: 11479235
[TBL] [Abstract][Full Text] [Related]
14. In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.
Pondarré C; Strumberg D; Fujimori A; Torres-León R; Pommier Y
Nucleic Acids Res; 1997 Oct; 25(20):4111-6. PubMed ID: 9321666
[TBL] [Abstract][Full Text] [Related]
15. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.
Maede Y; Shimizu H; Fukushima T; Kogame T; Nakamura T; Miki T; Takeda S; Pommier Y; Murai J
Mol Cancer Ther; 2014 Jan; 13(1):214-20. PubMed ID: 24130054
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of resistance to topoisomerase I-targeting drugs.
Rasheed ZA; Rubin EH
Oncogene; 2003 Oct; 22(47):7296-304. PubMed ID: 14576839
[TBL] [Abstract][Full Text] [Related]
17. Proteasome-dependent processing of topoisomerase I-DNA adducts into DNA double strand breaks at arrested replication forks.
Lin CP; Ban Y; Lyu YL; Liu LF
J Biol Chem; 2009 Oct; 284(41):28084-28092. PubMed ID: 19666469
[TBL] [Abstract][Full Text] [Related]
18. Cellular processing determinants for the activation of damage signals in response to topoisomerase I-linked DNA breakage.
Huang TH; Chen HC; Chou SM; Yang YC; Fan JR; Li TK
Cell Res; 2010 Sep; 20(9):1060-75. PubMed ID: 20603643
[TBL] [Abstract][Full Text] [Related]
19. The bromodomain and extra-terminal domain inhibitor JQ1 synergistically sensitizes human colorectal cancer cells to topoisomerase I inhibitors through repression of Mre11-mediated DNA repair pathway.
Lei L; Xie X; He L; Chen K; Lv Z; Zhou B; Li Y; Hu W; Zhou Z
Invest New Drugs; 2021 Apr; 39(2):362-376. PubMed ID: 32981006
[TBL] [Abstract][Full Text] [Related]
20. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
